SG183875A1 - Kinase inhibitors and method of treating cancer with same - Google Patents

Kinase inhibitors and method of treating cancer with same Download PDF

Info

Publication number
SG183875A1
SG183875A1 SG2012065090A SG2012065090A SG183875A1 SG 183875 A1 SG183875 A1 SG 183875A1 SG 2012065090 A SG2012065090 A SG 2012065090A SG 2012065090 A SG2012065090 A SG 2012065090A SG 183875 A1 SG183875 A1 SG 183875A1
Authority
SG
Singapore
Prior art keywords
mmol
cancer
indazol
title compound
cyclopropane
Prior art date
Application number
SG2012065090A
Other languages
English (en)
Inventor
Peter Brent Sampson
Yong Liu
Sze-Wan Li
Bryan T Forrest
Heinz W Pauls
Louise G Edwards
Miklos Feher
Narendra Kumar B Patel
Radoslaw Laufer
Guohua Pan
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2010/000518 external-priority patent/WO2010115279A1/en
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of SG183875A1 publication Critical patent/SG183875A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
SG2012065090A 2010-04-06 2011-04-06 Kinase inhibitors and method of treating cancer with same SG183875A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32133210P 2010-04-06 2010-04-06
US32132910P 2010-04-06 2010-04-06
PCT/CA2010/000518 WO2010115279A1 (en) 2009-04-06 2010-04-06 Kinase inhibitors and method of treating cancer with same
PCT/CA2011/000386 WO2011123946A1 (en) 2010-04-06 2011-04-06 Kinase inhibitors and method of treating cancer with same

Publications (1)

Publication Number Publication Date
SG183875A1 true SG183875A1 (en) 2012-10-30

Family

ID=44761967

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2012065090A SG183875A1 (en) 2010-04-06 2011-04-06 Kinase inhibitors and method of treating cancer with same

Country Status (25)

Country Link
US (9) US8263596B2 (enExample)
EP (2) EP2556070B1 (enExample)
JP (1) JP5442906B2 (enExample)
KR (1) KR101782668B1 (enExample)
CN (1) CN102892766B (enExample)
AU (1) AU2011238384B2 (enExample)
BR (1) BR112012025496B1 (enExample)
CY (1) CY1118610T1 (enExample)
DK (1) DK2556071T3 (enExample)
EA (1) EA023173B1 (enExample)
ES (2) ES2603613T3 (enExample)
HR (1) HRP20161498T1 (enExample)
HU (1) HUE030651T2 (enExample)
IL (1) IL221556A (enExample)
LT (1) LT2556071T (enExample)
ME (1) ME02545B (enExample)
MX (1) MX2012011516A (enExample)
NZ (1) NZ602350A (enExample)
PL (1) PL2556071T3 (enExample)
PT (1) PT2556071T (enExample)
SG (1) SG183875A1 (enExample)
SI (1) SI2556071T1 (enExample)
SM (1) SMT201600430B (enExample)
TW (1) TWI516262B (enExample)
WO (2) WO2011123946A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2709536C (en) 2007-12-21 2016-05-31 University Health Network Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
JP5629752B2 (ja) * 2009-04-06 2014-11-26 ユニバーシティ・ヘルス・ネットワークＵｎｉｖｅｒｓｉｔｙ Ｈｅａｌｔｈ Ｎｅｔｗｏｒｋ キナーゼインヒビターおよびこれを用いた癌の治療方法
SI2556071T1 (sl) 2010-04-06 2016-12-30 University Health Network Kinazni inhibitorji in njihova uporaba pri zdravljenju raka
US8933070B2 (en) 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
DK3444238T3 (da) * 2012-07-27 2022-01-03 Sato Pharma Fremgangsmåde til fremstilling af difluormethylenforbindelser
WO2015054781A1 (en) 2013-10-18 2015-04-23 University Health Network Treatment for pancreatic cancer
CN105764899B (zh) * 2013-10-18 2021-06-01 大学健康网络 Plk-4抑制剂的盐和晶型
CN104130175A (zh) * 2014-06-13 2014-11-05 天津科技大学 不同位置取代吲哚酮类衍生物及其应用
CN110072865B (zh) 2017-02-08 2022-02-11 中国医药研究开发中心有限公司 吡咯并芳杂环类化合物及其制备方法和医药用途
CN108947961B (zh) * 2017-05-18 2021-06-04 四川大学 吲唑类衍生物及其制备方法和用途
AU2018328773B2 (en) * 2017-09-08 2023-11-16 University Health Network Combination therapies for inhibition of Polo-like Kinase 4
EP3877371A4 (en) 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES USED AS JANUS KINASE 2 INHIBITORS AND ASSOCIATED USES
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
EP3876930A4 (en) 2018-11-07 2022-07-20 Dana-Farber Cancer Institute, Inc. BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND THEIR USES
BR112021021106A2 (pt) 2019-04-24 2021-12-14 Univ Health Network Forma cristalina s4 do inibidor plk4 fumarato (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimetilmorfolino)metil)estiril)-1h-imidazol-6-il)-5'-metoxiespiro[ciclopropano-1,3'-indolin]-2'ona
JP2023505301A (ja) * 2019-12-06 2023-02-08 ユニバーシティー ヘルス ネットワーク 急性骨髄性白血病または骨髄異形成症候群に対する治療
WO2021226261A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN112250614B (zh) * 2020-10-20 2022-02-01 苏州大学 3-螺三元环吲哚酮衍生物的合成方法
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202300485A (zh) * 2021-03-02 2023-01-01 大陸商上海齊魯製藥研究中心有限公司 Plk4抑制劑及其用途
AU2022272184A1 (en) 2021-05-11 2023-11-30 Oric Pharmaceuticals, Inc. Polo like kinase 4 inhibitors
CN115677682B (zh) * 2021-07-30 2023-07-18 上海齐鲁制药研究中心有限公司 螺环类plk4抑制剂及其用途
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
JP7782035B2 (ja) 2021-11-09 2025-12-08 エイジャックス セラピューティクス， インコーポレイテッド Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
WO2024006379A1 (en) * 2022-06-30 2024-01-04 Axonis Therapeutics, Inc. Methods and compounds for inhibiting mkk7 enzymes
WO2024209363A1 (en) 2023-04-06 2024-10-10 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3310891A1 (de) 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US5182397A (en) * 1990-05-31 1993-01-26 American Cyanamid Company Aryloxyspiroalkylindolinone herbicides
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
EP1247803A3 (en) 1996-08-23 2002-10-16 Sugen, Inc. Indolinone compounds suitable for modulation of protein kinases
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
AU5468499A (en) 1998-08-04 2000-02-28 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
EP1165513A1 (en) 1999-03-24 2002-01-02 Sugen, Inc. Indolinone compounds as kinase inhibitors
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6706709B2 (en) 2000-06-02 2004-03-16 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
TW200406385A (en) 2002-05-31 2004-05-01 Eisai Co Ltd Pyrazole compound and pharmaceutical composition containing the same
US7148249B2 (en) * 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
AU2003286604A1 (en) * 2002-10-21 2004-05-13 Irm Llc Oxindoles with anti-hiv activity
US20070167488A1 (en) 2003-12-16 2007-07-19 Leo Pharma A/S Novel therapeutic use
US20050211590A1 (en) 2004-03-26 2005-09-29 Mcclure George K Protective cover for medical devices
DE102005005395A1 (de) 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
US7309787B2 (en) * 2005-07-13 2007-12-18 Allergan, Inc. Kinase inhibitors
WO2007058626A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
US20070135509A1 (en) 2005-12-09 2007-06-14 Blackburn Thomas P Indolone compounds useful to treat cognitive impairment
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2007109026A2 (en) 2006-03-15 2007-09-27 The Trustees Of Columbia University In The City Of New York Pten compositions and methods for detecting breast cancer
GB0606234D0 (en) 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
EP2181108A2 (en) * 2007-06-12 2010-05-05 Boehringer Ingelheim International GmbH 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
WO2009042711A1 (en) 2007-09-25 2009-04-02 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
CA2706075A1 (en) 2007-11-20 2009-05-28 University Health Network Cancer diagnostic and therapeutic methods that target plk4/sak
JP2009173629A (ja) * 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体
CA2709536C (en) * 2007-12-21 2016-05-31 University Health Network Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
JP5593234B2 (ja) * 2008-03-11 2014-09-17 ユニバーシティー ヘルス ネットワーク ニューロペプチドｙ５ｒ（ｎｐｙ５ｒ）アンタゴニストを使用して癌を治療する方法
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
AU2009271406A1 (en) 2008-06-16 2010-01-21 Tigris Pharmaceuticals, Inc. Methods for determining sensitivity to aminoflavones
DE102008040187A1 (de) * 2008-07-04 2010-01-07 Robert Bosch Gmbh Sensorelement, Verfahren zu seiner Herstellung sowie Verwendung
AU2009279936A1 (en) 2008-08-05 2010-02-11 Banyu Pharmaceutical Co., Ltd. Therapeutic compounds
JP5629752B2 (ja) * 2009-04-06 2014-11-26 ユニバーシティ・ヘルス・ネットワークＵｎｉｖｅｒｓｉｔｙ Ｈｅａｌｔｈ Ｎｅｔｗｏｒｋ キナーゼインヒビターおよびこれを用いた癌の治療方法
WO2011069298A1 (en) * 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
JP5056876B2 (ja) 2010-03-19 2012-10-24 Ｊｆｅスチール株式会社 冷間加工性と焼入れ性に優れた熱延鋼板およびその製造方法
SI2556071T1 (sl) 2010-04-06 2016-12-30 University Health Network Kinazni inhibitorji in njihova uporaba pri zdravljenju raka
US8933070B2 (en) 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
WO2012048411A1 (en) 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
EA024026B1 (ru) 2010-11-25 2016-08-31 Рациофарм Гмбх Новые соли и полиморфные формы афатиниба
AU2012223448B2 (en) 2011-02-28 2017-03-16 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
GB201109966D0 (en) 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating pten mutated or deficient cancer
US9580390B2 (en) 2011-10-12 2017-02-28 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
CN105764899B (zh) 2013-10-18 2021-06-01 大学健康网络 Plk-4抑制剂的盐和晶型
WO2015054781A1 (en) 2013-10-18 2015-04-23 University Health Network Treatment for pancreatic cancer

Also Published As

Publication number Publication date
KR101782668B1 (ko) 2017-09-27
AU2011238384B2 (en) 2015-02-19
CY1118610T1 (el) 2017-07-12
NZ602350A (en) 2014-05-30
US20170226088A1 (en) 2017-08-10
EP2556071B1 (en) 2016-08-17
US20130096301A1 (en) 2013-04-18
BR112012025496B1 (pt) 2021-02-23
US8481533B2 (en) 2013-07-09
IL221556A (en) 2015-04-30
SMT201600430B (it) 2017-01-10
CN102892766A (zh) 2013-01-23
WO2011123946A1 (en) 2011-10-13
US20150133677A1 (en) 2015-05-14
US20180282306A1 (en) 2018-10-04
WO2011123947A1 (en) 2011-10-13
EP2556071A1 (en) 2013-02-13
US20180105511A1 (en) 2018-04-19
MX2012011516A (es) 2013-03-08
ME02545B (me) 2017-02-20
US20160045511A1 (en) 2016-02-18
US20140045838A1 (en) 2014-02-13
EP2556070B1 (en) 2017-06-07
PL2556071T3 (pl) 2017-02-28
SI2556071T1 (sl) 2016-12-30
US9907800B2 (en) 2018-03-06
JP5442906B2 (ja) 2014-03-19
US8263596B2 (en) 2012-09-11
US9579327B2 (en) 2017-02-28
EP2556070A4 (en) 2013-10-23
CN102892766B (zh) 2015-05-20
WO2011123946A8 (en) 2011-12-08
DK2556071T3 (en) 2016-12-12
EA023173B1 (ru) 2016-04-29
EP2556071A4 (en) 2013-09-04
TW201134471A (en) 2011-10-16
HRP20161498T1 (hr) 2016-12-16
WO2011123947A8 (en) 2011-12-22
BR112012025496A2 (pt) 2020-08-18
KR20130108065A (ko) 2013-10-02
US10077255B2 (en) 2018-09-18
ES2603613T3 (es) 2017-02-28
US20110263598A1 (en) 2011-10-27
US8921545B2 (en) 2014-12-30
US20120264800A1 (en) 2012-10-18
JP2013523784A (ja) 2013-06-17
US9796703B2 (en) 2017-10-24
EP2556070A1 (en) 2013-02-13
US10358436B2 (en) 2019-07-23
HUE030651T2 (en) 2017-05-29
LT2556071T (lt) 2017-01-25
PT2556071T (pt) 2016-11-22
TWI516262B (zh) 2016-01-11
EA201270752A1 (ru) 2013-04-30
AU2011238384A1 (en) 2012-09-27
US9139563B2 (en) 2015-09-22
ES2639757T3 (es) 2017-10-30

Similar Documents

Publication Publication Date Title
EP2556071B1 (en) Kinase inhibitors and their use in treating cancer
USRE47731E1 (en) Kinase inhibitors and method of treating cancer with same
CN109219604B (zh) 四氢异喹啉雌激素受体调节剂及其用途
WO2012048411A1 (en) Plk-4 inhibitors and method of treating cancer with same
HK1180315B (en) Kinase inhibitors and their use in treating cancer
CA2791324A1 (en) Kinase inhibitors and method of treating cancer with same
TW202108576A (zh) 用於治療ｈｂｖ感染或ｈｂｖ誘發的疾病之醯胺衍生物